84 related articles for article (PubMed ID: 33423358)
1. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
[TBL] [Abstract][Full Text] [Related]
2. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
Pothuraju R; Rachagani S; Krishn SR; Chaudhary S; Nimmakayala RK; Siddiqui JA; Ganguly K; Lakshmanan I; Cox JL; Mallya K; Kaur S; Batra SK
Mol Cancer; 2020 Feb; 19(1):37. PubMed ID: 32098629
[TBL] [Abstract][Full Text] [Related]
3. SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer.
Matsumoto Y; Itou J; Sato F; Toi M
Cancer Med; 2018 Feb; 7(2):454-462. PubMed ID: 29356399
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
Garza-Treviño EN; Martínez-Rodríguez HG; Delgado-González P; Solís-Coronado O; Ortíz-Lopez R; Soto-Domínguez A; Treviño VM; Padilla-Rivas GR; Islas-Cisneros JF; Quiroz-Reyes AG; Said-Fernández SL
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396431
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PRMT5-mediated regulation of DKK1 sensitizes colorectal cancer cells to chemotherapy.
Abumustafa W; Castven D; Becker D; Salih SS; Manzoor S; Zamer BA; Talaat I; Hamad M; Marquardt JU; Muhammad JS
Cell Signal; 2024 Jul; 119():111166. PubMed ID: 38588876
[TBL] [Abstract][Full Text] [Related]
6. Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20.
Fatima I; Ahmad R; Barman S; Gowrikumar S; Pravoverov K; Primeaux M; Fisher KW; Singh AB; Dhawan P
Br J Cancer; 2024 Apr; 130(6):1046-1058. PubMed ID: 38278978
[TBL] [Abstract][Full Text] [Related]
7. Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance.
Zheng H; Liu J; Cheng Q; Zhang Q; Zhang Y; Jiang L; Huang Y; Li W; Zhao Y; Chen G; Yu F; Liu L; Li Y; Liao X; Xu L; Xiao Y; Zheng Z; Li M; Wang H; Hu G; Du L; Chen Q
Nat Cancer; 2024 Apr; 5(4):572-589. PubMed ID: 38291304
[TBL] [Abstract][Full Text] [Related]
8. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients.
Kong J; Lee H; Kim D; Han SK; Ha D; Shin K; Kim S
Nat Commun; 2020 Oct; 11(1):5485. PubMed ID: 33127883
[TBL] [Abstract][Full Text] [Related]
9. A pair of primary colorectal cancer-derived and corresponding synchronous liver metastasis-derived organoid cell lines.
Cheng F; Li P; Xu S; Zhang C; Liang H; Ding Z
Aging (Albany NY); 2024 Feb; 16(5):4396-4422. PubMed ID: 38407980
[TBL] [Abstract][Full Text] [Related]
10. Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism.
Cong B; Thakur T; Uribe AH; Stamou E; Gopinath S; Maddocks O; Cagan R
bioRxiv; 2023 Dec; ():. PubMed ID: 38187524
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study.
Wang T; Pan W; Zheng H; Zheng H; Wang Z; Li JJ; Deng C; Yan J
Dis Colon Rectum; 2021 Jul; 64(7):833-850. PubMed ID: 33709991
[TBL] [Abstract][Full Text] [Related]
12. Gel-Free 3D Tumoroids with Stem Cell Properties Modeling Drug Resistance to Cisplatin and Imatinib in Metastatic Colorectal Cancer.
Sogawa C; Eguchi T; Namba Y; Okusha Y; Aoyama E; Ohyama K; Okamoto K
Cells; 2021 Feb; 10(2):. PubMed ID: 33562088
[TBL] [Abstract][Full Text] [Related]
13. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.
Harada K; Sakamoto N; Ukai S; Yamamoto Y; Pham QT; Taniyama D; Honma R; Maruyama R; Takashima T; Ota H; Takemoto Y; Tanabe K; Ohdan H; Yasui W
Gastric Cancer; 2021 Nov; 24(6):1264-1277. PubMed ID: 34272617
[TBL] [Abstract][Full Text] [Related]
14. The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.
Wang Z; Chen W; Zuo L; Xu M; Wu Y; Huang J; Zhang X; Li Y; Wang J; Chen J; Wang H; Sun H
Cancer Commun (Lond); 2022 Mar; 42(3):245-265. PubMed ID: 35234370
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer drug resistance utilizing organoid technology.
Chai C; Ji P; Xu H; Tang H; Wang Z; Zhang H; Zhou W
Biomed Pharmacother; 2023 Feb; 158():114098. PubMed ID: 36528918
[TBL] [Abstract][Full Text] [Related]
16. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
[TBL] [Abstract][Full Text] [Related]
17. Single-Cell Transcriptome Analysis Uncovers Intratumoral Heterogeneity and Underlying Mechanisms for Drug Resistance in Hepatobiliary Tumor Organoids.
Zhao Y; Li ZX; Zhu YJ; Fu J; Zhao XF; Zhang YN; Wang S; Wu JM; Wang KT; Wu R; Sui CJ; Shen SY; Wu X; Wang HY; Gao D; Chen L
Adv Sci (Weinh); 2021 Jun; 8(11):e2003897. PubMed ID: 34105295
[TBL] [Abstract][Full Text] [Related]
18. Base editing screens map mutations affecting interferon-γ signaling in cancer.
Coelho MA; Cooper S; Strauss ME; Karakoc E; Bhosle S; Gonçalves E; Picco G; Burgold T; Cattaneo CM; Veninga V; Consonni S; Dinçer C; Vieira SF; Gibson F; Barthorpe S; Hardy C; Rein J; Thomas M; Marioni J; Voest EE; Bassett A; Garnett MJ
Cancer Cell; 2023 Feb; 41(2):288-303.e6. PubMed ID: 36669486
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers.
Li L; Selaru FM
Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
